Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.
Indian J Ophthalmol. 2021 Mar;69(3):563-567. doi: 10.4103/ijo.IJO_1665_20.
The aim of this study was to evaluate tumor control of OSSN with topical IFNα2b alone based on tumor configuration (flat versus (vs.) dome-shaped).
Retrospective, nonrandomized, interventional cohort study on 64 consecutive tumors in 63 patients with OSSN treated with topical IFNα2b. Topical IFNα2b (1 million international units/cc) was compounded and provided by the Thomas Jefferson University Hospital Pharmacy to be refrigerated and applied 4 times daily until biomicroscopic evidence of tumor resolution was observed.
The tumor configuration was flat (n = 15, 23%) or dome-shaped (n = 49, 77%). A comparison (flat vs. dome-shaped) revealed dome-shaped with older mean patient age at presentation (62 vs. 70 years, P = 0.04), greater patient history of smoking (13% vs. 42%, P = 0.04), greater corneal involvement (7% vs. 82%, P < 0.001), larger mean basal diameter (5.5 vs. 12.4 mm, P = 0.001) and mean thickness (1.9 vs. 4.3, P = 0.002), and longer mean duration IFNα2b therapy (3.7 vs. 6.3 months, P = 0.002). There was no difference in mean follow-up time (22.2 vs 23.1 months) or time to complete response (5.0 vs. 6.1 months). There was no difference in achievement of complete tumor control with IFNα2b alone (93% vs. 96%). There were no cases with metastasis or death.
Topical IFNα2b alone shows excellent overall tumor control of 95% with no difference in efficacy based on tumor configuration.
本研究旨在评估基于肿瘤形态（扁平 vs. 穹隆状），单纯使用局部干扰素 α2b 治疗 OSSN 的肿瘤控制情况。
对托马斯杰斐逊大学医院药房配制并冷藏的局部干扰素 α2b（100 万国际单位/cc）进行回顾性、非随机、干预性队列研究，共对 63 例 OSSN 患者的 64 个连续肿瘤进行治疗，每日 4 次局部应用。直到观察到肿瘤消退的生物显微镜证据。
肿瘤形态为扁平（n = 15，23%）或穹隆状（n = 49，77%）。对比（扁平 vs. 穹隆状）显示，穹隆状的患者在就诊时的平均年龄更大（62 岁 vs. 70 岁，P = 0.04）、有更多的吸烟史（13% vs. 42%，P = 0.04）、更大的角膜受累（7% vs. 82%，P < 0.001）、更大的平均基底直径（5.5 毫米 vs. 12.4 毫米，P = 0.001）和平均厚度（1.9 毫米 vs. 4.3 毫米，P = 0.002），以及更长的平均干扰素 α2b 治疗时间（3.7 个月 vs. 6.3 个月，P = 0.002）。平均随访时间（22.2 个月 vs. 23.1 个月）或完全缓解时间（5.0 个月 vs. 6.1 个月）无差异。单纯使用干扰素 α2b 治疗完全肿瘤控制的成功率无差异（93% vs. 96%）。无转移或死亡病例。
单纯使用局部干扰素 α2b 治疗 OSSN 的总体肿瘤控制率达到 95%，疗效与肿瘤形态无关。
